Filing identity and reporting period
The supplied filing is Access Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2013. This does not match the request metadata naming Abeona Therapeutics, Inc.; verify the issuer before relying on this summary.
Business context and key financial metrics
Access described itself as an emerging biopharmaceutical company focused on drug-delivery technologies. MuGard, its marketed oral-mucositis product, was licensed to AMAG Pharmaceuticals in the U.S. on June 6, 2013. ProLindac was in Phase 2, with no new U.S. or European trials underway; other platforms were preclinical and available for partnering.
- Second-quarter revenue: $467,000, versus $690,000 a year earlier. This included $380,000 in MuGard product sales, $84,000 in licensing revenue, and $3,000 in royalties.
- Six-month revenue: $1.691 million, versus $2.527 million. MuGard sales rose to $1.542 million from $1.169 million, while licensing revenue fell to $146,000 from $1.322 million, largely because 2012 included recognition of previously deferred European license fees and a termination fee.
- Operating results: Operating loss was $1.921 million for Q2 and $2.424 million for the six months. Net income allocable to common shareholders was $867,000 for Q2 and $4.221 million for six months, compared with losses of $11.039 million and $16.371 million, respectively, in 2012. The 2013 profits included substantial noncash gains from changes in the fair value of preferred-stock derivatives: $3.270 million for Q2 and $8.050 million for six months.
- Costs: Q2 R&D expense declined to $197,000 from $654,000, while selling, general and administrative expense increased to $2.137 million from $1.406 million. For six months, R&D was $520,000 versus $1.404 million, SG&A was $3.475 million versus $3.069 million, and total expenses were $4.115 million versus $4.668 million.
- Cash flow and liquidity: Cash and equivalents were $1.798 million at June 30, 2013, compared with $396,000 at year-end. Six-month operating cash flow was positive $1.391 million, affected by a $3.154 million increase in deferred revenue. Management separately reported a net cash burn rate of approximately $349,000 per month.
- Balance sheet: Working-capital deficit was $5.422 million, versus $4.948 million at December 31, 2012. Total liabilities were $14.750 million and stockholders’ deficit was $12.353 million. The balance sheet lists no outstanding interest-bearing debt; the $2.75 million secured promissory note had been paid off in November 2012.
- Margins: The filing does not provide a clear consolidated margin measure. Q2 MuGard product costs were $53,000 against $380,000 in product sales.
Material changes versus the prior comparable period
- Q2 total revenue declined 32% year over year; six-month revenue declined 33%, principally reflecting the absence of the prior-year European license termination-related revenue.
- MuGard U.S. sales were lower in Q2 partly because Access recorded product sales for only two months before licensing the product to AMAG. After the license, revenue was expected to come from royalties.
- Reduced scientific staffing, completed clinical work, and closure of the laboratory lowered R&D spending. Legal, stock-compensation, consulting, and MuGard transition costs increased SG&A.
- Reported profitability reversed sharply from 2012 losses, but results were significantly affected by fair-value accounting for convertible preferred-stock derivatives. The six-month 2012 comparison also included a $2.316 million warrant-extension expense.
Outlook, risks, contingencies, and unusual items
- Management expected cash, MuGard revenue, and anticipated license receipts to fund the current operating level into the first quarter of 2014, but said additional financing would be required to continue operations beyond that. The company warned that failure to raise capital or secure licensing/royalty receipts could jeopardize its ability to continue as a going concern.
- The $3.3 million AMAG upfront license fee was recorded as deferred revenue and was to be recognized over the ten-year license term. AMAG also purchased existing MuGard inventory; Access was entitled to tiered double-digit royalties on net sales.
- China partners had received an acceptance letter providing marketing approval for MuGard and anticipated sales beginning in Q3 2013. The filing reports this as a partner expectation, not confirmed sales.
- Access expected losses for several years and cited risks involving research and development, clinical trials, regulatory approvals, financing, licensing partners, and future product and royalty revenue.
- Preferred dividends accrued during the first half totaled $1.460 million; total dividends payable at June 30 were $5.032 million. The company also accrued $857,000 in liquidated damages related to registration obligations for certain securities.
- Disclosure controls were deemed ineffective because a previously identified material weakness—insufficient review and segregation of duties in financial reporting—remained unremediated. Management said it did not believe the weakness affected the current-period financial statements.
- A shareholder lawsuit was dismissed with judgment for defendants on August 12, 2013. The filing reported no other material pending legal proceedings.
Most important facts to verify
- Confirm the issuer: the filing identifies Access Pharmaceuticals, not Abeona Therapeutics.
- Verify cash runway and financing needs, including the assumptions behind the projected runway into Q1 2014.
- Assess operating performance apart from the large, noncash preferred-stock derivative gains and the deferred AMAG upfront fee.
- Review preferred-stock dividend terms, accrued amounts, conversion dilution, and registration-related damages. The filing contains differing descriptions of Series B dividend timing, and reported Series A conversion-share counts differ between sections.
- Confirm whether anticipated MuGard sales in China began and whether AMAG royalties developed as expected.
- Track remediation of the material weakness in internal controls.